NCI-Designated Cancer Center at Sanford Burnham Prebys

One of only seven National Cancer Institute-designated Basic Laboratory Cancer Centers in the nation.
Cancer Center researchers

Taking aim at cancer

“Our Cancer Center is committed to performing impactful translational multi-disciplinary research that addresses unmet clinical needs relevant to the diagnosis and treatment of cancer.”

– Ze'ev Ronai, Ph.D., Center Director

Director's Statement

 

Achieving our goals through collaboration

Our scientists are always looking for novel ideas, partners and new ways of doing groundbreaking research to target cancer.

Programs

Cancer Genome and Epigenetics Program

Understanding the cells that give rise to tumors and the signals allowing them to expand uncontrollably will help us learn how to defeat cancer.

Learn More

Cancer Metabolism and Microenvironment Program

Just like a complex machine is made up of synchronized parts, cancer is the sum of highly organized cells and molecules that relay information causing the tumor to grow.

Learn More

Cancer Molecular Therapeutics Program

We are using the most sophisticated technologies to discover new anti-cancer therapeutics based on novel insights into cancer biology.
 

Learn More

Latest news

Publications

PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.

Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S, Ronai ZA

Sci Transl Med 2020 Jul 8 ;12(551)

Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death.

Sakuma S, Raices M, Borlido J, Guglielmi V, Zhu EYS, D'Angelo MA

Cancer Discov 2021 Jan ;11(1):176-193

Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells.

Galenkamp KMO, Sosicka P, Jung M, Recouvreux MV, Zhang Y, Moldenhauer MR, Brandi G, Freeze HH, Commisso C

Cancer Discov 2020 Jun ;10(6):822-835

TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation.

Hao X, Zhao B, Towers M, Liao L, Monteiro EL, Xu X, Freeman C, Peng H, Tang HY, Havas A, Kossenkov AV, Berger SL, Adams PD, Speicher DW, Schultz D, Marmorstein R, Zaret KS, Zhang R

Nat Aging 2024 Jan 24 ;

Detection of Genomic Structural Variations Associated with Drug Sensitivity and Resistance in Acute Leukemia.

Finlay D, Murad R, Hong K, Lee J, Pang AWC, Lai CY, Clifford B, Burian C, Mason J, Hastie AR, Yin J, Vuori K

Cancers (Basel) 2024 Jan 18 ;16(2)

Accurate identification of structural variations from cancer samples.

Li L, Hong C, Xu J, Chung CY, Leung AK, Boncan DAT, Cheng L, Lo KW, Lai PBS, Wong J, Zhou J, Cheng AS, Chan TF, Yue F, Yip KY

Brief Bioinform 2023 Nov 22 ;25(1)

Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis.

Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP

Cancer Res 2024 Jan 17 ;

Conditional hepatocyte ablation of PDIA1 uncovers indispensable roles in both APOB and MTTP folding to support VLDL secretion.

Chen Z, Wang S, Pottekat A, Duffey A, Jang I, Chang BH, Cho J, Finck BN, Davidson NO, Kaufman RJ

Mol Metab 2024 Jan 9 ;80:101874

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters.

Diego JG, Singh G, Jangra S, Handrejk K, Laporte M, Chang LA, El Zahed SS, Pache L, Chang MW, Warang P, Aslam S, Mena I, Webb BT, Benner C, García-Sastre A, Schotsaert M

PLoS Pathog 2024 Jan ;20(1):e1011805

Show All Publications